Fulcrum Therapeutics merges with Slate in $245M migraine biotech deal. August 17, 2026 Key points. * Fulcrum Therapeutics will merge with migraine biotech Slate Medicines in an all-stock transaction expected to close in the fourth quarter of 2026, pending approvals. The combined company will be renamed Slate Medicines and trade under the Nasdaq ticker SLTE. * The deal includes a $245 million private placement; pre-merger Fulcrum shareholders are expected to receive about 5% of the combined company and a special cash dividend of approximately $270 million. The combined company is projected to have cash runway into 2029. * Slate's lead drug candidate, SLTE-1009, targets PACAP and VIP and is set to enter Phase I testing, with safety and pharmacokinetic data expected in mid-2027. Slate also plans to advance its bispecific SLTE-2100, targeting PACAP, VIP and CGRP, into clinical testing in the second half of 2027. * Five stocks to consider instead of Fulcrum Therapeutics. Fulcrum Therapeutics NASDAQ: FULC has entered into an all-stock merger agreement with privately held Slate Medicines, a migraine-focused biotechnology company, in a transaction expected to close in the fourth quarter of 2026, subject to stockholder approval and customary closing conditions. Alex Sapir, Fulcrum's president and chief executive officer, said the company pursued a comprehensive review of strategic alternatives following its June announcement regarding pociredir. He said Fulcrum's board and management concluded that combining with Slate offered an opportunity to create long-term value for stockholders. Following the transaction, the combined company is expected to be renamed Slate Medicines and trade on Nasdaq under the ticker symbol SLTE. Slate Chief Executive Officer Greg Oakes is expected to become CEO of the combined company, while Slate's current senior management team will operate the business. Slate's board is also expected to become the board of the combined company. Ownership, financing and dividend. The transaction is accompanied by a $245 million private placement of Slate common stock and common stock equivalents. The financing is led by Frazier Life Sciences, with participation from Forbion, RA Capital Management, Deep Track Capital, Foresite Capital, OrbiMed, RTW Investments and Mingxin Capital. On a fully diluted basis, pre-merger Fulcrum stockholders are expected to own approximately 5% of the combined company. Pre-merger Slate stockholders are expected to own about 55.9%, while private-placement investors are expected to own approximately 39.1%. Sapir said Fulcrum expects to contribute a net cash balance of $20.3 million at closing in exchange for the 5% ownership stake. Fulcrum also expects to pay a special cash dividend of approximately $270 million to pre-merger Fulcrum stockholders, using additional cash expected to be available at closing. The companies expect the combined company's cash balance to provide operating runway into 2029. Slate's migraine pipeline. Slate was founded to develop potentially best-in-class, next-generation treatments for migraine, according to Oakes. He described migraine as a disabling neurological disease that disproportionately affects women and said existing CGRP-targeted treatments have left a substantial number of patients without adequate responses. Oakes said that in pivotal chronic migraine prevention studies of CGRP-targeted therapeutics, about half of patients achieved more than a 50% reduction in monthly migraine days, while 20% achieved more than a 75% reduction. He said the market for CGRP-targeted therapies exceeded $5 billion in 2025 and is projected to more than double to more than $10 billion at peak. Discover more AI infrastructure stocks Financial Markets News Slate's lead program, SLTE-1009, is a monoclonal antibody designed to bind PACAP and VIP, two neuropeptides involved in migraine pathophysiology. The company believes that blocking both targets could potentially provide greater efficacy than therapies targeting PACAP alone. The antibody was engineered with half-life extension and could support quarterly subcutaneous administration. * Slate has received clearance to begin a Phase I healthy-volunteer study of SLTE-1009 in Australia. * Top-line safety and pharmacokinetic data are anticipated in mid-2027. * The company plans to begin a Phase II dose-ranging study in migraine patients in the second half of 2027 following the Phase I readout. Slate is also developing SLTE-2100, a bispecific antibody targeting PACAP, VIP and CGRP. The program is currently in lead optimization and is expected to enter clinical testing in the second half of 2027. The company also disclosed a third, undisclosed migraine program. Oakes said the financing and existing cash are expected to support several anticipated development milestones, including SLTE-1009's Phase I and Phase II studies, advancement of SLTE-2100 into clinical trials and through a Phase IIa proof-of-concept study, and continued expansion of Slate's pipeline. About Fulcrum Therapeutics (NASDAQ:FULC). Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small-molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company's core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms. Fulcrum's most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Fulcrum Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fulcrum Therapeutics wasn't on the list. While Fulcrum Therapeutics currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys. Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you'll find 7 stocks that could play a major role in the next tech-driven market boom.

Fulcrum Therapeutics has discontinued its pociredir programme for sickle cell disease and launched a strategic review to explore alternatives including merger, acquisition or sale following US Food and Drug Administration concerns. The decision came after FDA feedback linked pociredir's mechanism to potential malignancy risks observed with Tazverik, another PRC2 inhibitor withdrawn in March 2026. The FDA concluded that any intervention targeting the PRC2 complex carries equivalent malignancy risk regardless of which subunit is targeted, effectively closing the regulatory pathway for pociredir despite clinical data showing robust fetal haemoglobin increases. The Cambridge-based clinical-stage biopharmaceutical company had $333.3 million in cash and marketable securities as of 31 March 2026. Fulcrum is implementing cost reductions whilst exploring strategic options.

Fulcrum Therapeutics reported a net loss of $22.2 million for Q1 2026, up from $20.4 million in Q1 2025, as the company advances its sickle cell disease treatment programme. The biotech firm ended the quarter with $333.3 million in cash, cash equivalents and marketable securities, providing runway into 2029. The company reported positive Phase 1b PIONEER trial data for pociredir in sickle cell disease, showing significant increases in fetal haemoglobin levels. Fulcrum initiated a long-term dosing trial and plans to begin a potential registration-enabling trial in the second half of 2026. Research and development expenses rose to $14.1 million from $13.4 million year-over-year, whilst general and administrative expenses increased to $8.1 million from $7 million, driven by higher employee compensation costs.